Nina Wressnigg

Title: Nina Wressnigg: Innovator in Vaccine Development

Introduction

Nina Wressnigg is a prominent inventor based in Vienna, Austria. She has made significant contributions to the field of vaccine development, particularly in relation to Lyme disease and influenza. With a total of 2 patents, her work showcases her dedication to advancing medical science.

Latest Patents

Wressnigg's latest patents include innovative compositions comprising chimeric OspA molecules. This invention focuses on developing chimeric OspA molecules for use in a new Lyme vaccine. The chimeric OspA molecules consist of the proximal portion from one OspA serotype and the distal portion from another, retaining the antigenic properties of both parent polypeptides. These molecules can be delivered alone or in combination to provide protection against various genospecies. Additionally, she has developed a modified influenza virus, which includes an influenza B virus M gene with a modification of at least one nucleotide proximate to the N-terminus of the M gene. This invention also outlines methods for preparing the modified influenza virus and its use in vaccine preparation.

Career Highlights

Throughout her career, Wressnigg has worked with notable companies such as Baxter Healthcare and Baxter International Inc. Her experience in these organizations has contributed to her expertise in vaccine research and development.

Collaborations

Wressnigg has collaborated with esteemed colleagues, including Brian A Crowe and Christian Kittel. These partnerships have further enriched her research endeavors and innovations.

Conclusion

Nina Wressnigg's contributions to vaccine development highlight her role as a leading inventor in the medical field. Her innovative patents and collaborations reflect her commitment to advancing healthcare solutions.